175 related articles for article (PubMed ID: 21669573)
1. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.
Yao M; Yao DF; Bian YZ; Zhang CG; Qiu LW; Wu W; Sai WL; Yang JL; Zhang HJ
Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):289-94. PubMed ID: 21669573
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of hepatic hypoxia-inducible factor-1alpha and its abnormal gene expression during the formation of hepatocellular carcinoma.
Yao DF; Jiang H; Yao M; Li YM; Gu WJ; Shen YC; Qiu LW; Wu W; Wu XH; Sai WL
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):407-13. PubMed ID: 19666411
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation.
Yan XD; Yao M; Wang L; Zhang HJ; Yan MJ; Gu X; Shi Y; Chen J; Dong ZZ; Yao DF
World J Gastroenterol; 2013 Sep; 19(36):6084-92. PubMed ID: 24106410
[TBL] [Abstract][Full Text] [Related]
4. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma.
Yao M; Yao DF; Bian YZ; Wu W; Yan XD; Yu DD; Qiu LW; Yang JL; Zhang HJ; Sai WL; Chen J
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):171-9. PubMed ID: 23558072
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
Wang L; Yao M; Pan LH; Qian Q; Yao DF
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
[TBL] [Abstract][Full Text] [Related]
6. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].
Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD
Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of hepatic nuclear-transcription factor-kappa B expression and quantitative analysis in rat hepatocarcinogenesis.
Wu W; Yao DF; Qiu LW; Sai WL; Shen JJ; Yu HB; Wu XH; Li YM; Wang YL; Gu WJ
Hepatobiliary Pancreat Dis Int; 2009 Oct; 8(5):504-9. PubMed ID: 19822494
[TBL] [Abstract][Full Text] [Related]
8. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma.
Yao M; Wang L; Fang M; Zheng W; Dong Z; Yao D
Biosci Trends; 2016 Nov; 10(5):337-343. PubMed ID: 27795482
[TBL] [Abstract][Full Text] [Related]
9. Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development.
Qiu LW; Yao DF; Zong L; Lu YY; Huang H; Wu W; Wu XH
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):406-11. PubMed ID: 18693177
[TBL] [Abstract][Full Text] [Related]
10. Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.
Wang L; Pan L; Yao M; Cai Y; Dong Z; Yao D
Oncotarget; 2016 Jul; 7(27):42150-42158. PubMed ID: 27286460
[TBL] [Abstract][Full Text] [Related]
11. Neighbor of Punc E11, a novel oncofetal marker for hepatocellular carcinoma.
Marquardt JU; Quasdorff M; Varnholt H; Curth HM; Mesghenna S; Protzer U; Goeser T; Nierhoff D
Int J Cancer; 2011 May; 128(10):2353-63. PubMed ID: 20658536
[TBL] [Abstract][Full Text] [Related]
12. Dynamic expression of hepatic GP73 mRNA and protein and circulating GP73 during hepatocytes malignant transformation.
Sai WL; Yao M; Shen SJ; Zheng WJ; Sun JY; Wu MN; Wang L; Yao DF
Hepatobiliary Pancreat Dis Int; 2020 Oct; 19(5):449-454. PubMed ID: 32171652
[TBL] [Abstract][Full Text] [Related]
13. Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.
Dong Z; Yao M; Wang L; Yang J; Yao D
Mini Rev Med Chem; 2014; 14(14):1183-93. PubMed ID: 25553423
[TBL] [Abstract][Full Text] [Related]
14. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review).
Montalbano M; Georgiadis J; Masterson AL; McGuire JT; Prajapati J; Shirafkan A; Rastellini C; Cicalese L
Oncol Rep; 2017 Mar; 37(3):1291-1300. PubMed ID: 28098909
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
16. Abnormal expression of
Zheng WJ; Yao M; Fang M; Wang L; Dong ZZ; Yao DF
World J Gastroenterol; 2018 Aug; 24(32):3650-3662. PubMed ID: 30166860
[TBL] [Abstract][Full Text] [Related]
17. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?
Abdelgawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
Asian Pac J Cancer Prev; 2013; 14(12):7345-9. PubMed ID: 24460300
[TBL] [Abstract][Full Text] [Related]
18. Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.
Yu D; Dong Z; Yao M; Wu W; Yan M; Yan X; Qiu L; Chen J; Sai W; Yao D
Tumour Biol; 2013 Apr; 34(2):661-8. PubMed ID: 23192642
[TBL] [Abstract][Full Text] [Related]
19. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.
Wang JY; Wang XK; Zhu GZ; Zhou X; Yao J; Ma XP; Wang B; Peng T
BMC Cancer; 2021 Apr; 21(1):462. PubMed ID: 33902495
[TBL] [Abstract][Full Text] [Related]
20. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
